ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations

With an upside potential of 121.45%, ADMA Biologics, Inc. (NASDAQ:ADMA) ranks among the stocks under $20 that will explode.

The company is navigating a sharp divide between bullish analyst sentiment and mounting legal scrutiny tied to allegations from earlier this year. On June 10, 2026, Raymond James analyst Ryan Deschner resumed coverage of ADMA Biologics, Inc. (NASDAQ:ADMA) with an “Outperform” rating and a $21 price target.

Deschner told investors that ADMA has transformed into a profitable, high-growth company over the past few years, and said its growth is insulated from “Most Favored Nation” policies, tariffs, and Medicare pricing negotiations, given the nature of its plasma-derived programs and its U.S.-based manufacturing and sales.

That bullish call came just days before TheFly reported on June 15, 2026, that ADMA Biologics, Inc. (NASDAQ:ADMA) is facing a federal securities lawsuit. ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations The suit alleges ADMA Biologics, Inc.

(NASDAQ:ADMA) inflated its flagship product’s revenues through channel stuffing and concealed a distribution relationship tied to an entity allegedly controlled by a senior executive. The complaint, filed in the U.S.

District Court for the District of New Jersey, claims ADMA and certain senior executives made materially false and misleading statements about revenue growth, internal controls, and related-party transactions. The allegations followed a Culper Research short-seller report published on March 24, 2026. ADMA Biologics, Inc.

(NASDAQ:ADMA) shares fell roughly 16.6% that day, another 15% on March 25, and an additional 13.9% on March 26, closing at $8.

29, down from about $13.59 before the report. Cantor Fitzgerald said the company’s response lacked specific feedback addressing the report’s claims.

ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics. It conducts operations through two business segments: ADMA BioManufacturing and Plasma Collection Center.

While we acknowledge the potential of ADMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News. With an upside potential of 121.

45%, ADMA Biologics, Inc. (NASDAQ:ADMA) ranks among the stocks under $20 that will explode. The company is navigating a sharp divide between bullish analyst sentiment and mounting legal scrutiny tied to allegations from earlier this year.

On June 10, 2026, Raymond James analyst Ryan Deschner resumed coverage of ADMA Biologics, Inc. (NASDAQ:ADMA) with an “Outperform” rating and a $21 price target. Deschner told investors that ADMA has transformed into a profitable, high-growth company over the past few years, and said its growth is insulated from “Most Favored Nation” policies, tariffs, and Medicare pricing negotiations, given the nature of its plasma-derived programs and its U.

S.-based manufacturing and sales. That bullish call came just days before TheFly reported on June 15, 2026, that ADMA Biologics, Inc.

(NASDAQ:ADMA) is facing a federal securities lawsuit. ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations The suit alleges ADMA Biologics, Inc. (NASDAQ:ADMA) inflated its flagship product’s revenues through channel stuffing and concealed a distribution relationship tied to an entity allegedly controlled by a senior executive.

The complaint, filed in the U.S. District Court for the District of New Jersey, claims ADMA and certain senior executives made materially false and misleading statements about revenue growth, internal controls, and related-party transactions.

The allegations followed a Culper Research short-seller report published on March 24, 2026. ADMA Biologics, Inc. (NASDAQ:ADMA) shares fell roughly 16.

6% that day, another 15% on March 25, and an additional 13.9% on March 26, closing at $8.29, down from about $13.

59 before the report. Cantor Fitzgerald said the company’s response lacked specific feedback addressing the report’s claims. ADMA Biologics, Inc.

(NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics. It conducts operations through two business segments: ADMA BioManufacturing and Plasma Collection Center. While we acknowledge the potential of ADMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.

If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshor